Scynexis

Yahoo Finance • 10 days ago

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low to mid single digit... Full story

Yahoo Finance • 12 days ago

Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections

Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat resistant fungal infections, including the Company’s next generation of triterpenoid antifungals (fun... Full story

Yahoo Finance • 24 days ago

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

SCYNEXIS to receive one-time payments totalling $24.8 million from GSK as part of the resolution of the disagreement related to the restart of the Phase 3 MARIO study in invasive candidiasis. Scynexis agreed to GSK’s request to terminate t... Full story

Yahoo Finance • last month

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasis Scynexis will promptly wind-down and terminate the MARIO study The payment from GSK, combined wit... Full story

Yahoo Finance • 3 months ago

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

Oral presentation will feature data demonstrating SCY-247 in vitro activity against C. auris strains, including isolates with mutations commonly associated with echinocandin-resistanceAdditional poster presentations highlight SCY-247’s bro... Full story

Yahoo Finance • 4 months ago

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six month anniversary of the new patient d... Full story

Yahoo Finance • 6 months ago

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold Resumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone due in six months; as previously... Full story

Yahoo Finance • 7 months ago

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

Ibrexafungerp clinical hold lifted by the FDA. SCYNEXIS working to resolve a disagreement with GSK involving the restart of the MARIO study. GSK remains committed to the commercialization of Brexafemme. Hansoh recently received Chinese (NM... Full story

Yahoo Finance • 9 months ago

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025. Four presentations for SCY-247 were accepted by the European Society of Clinical M... Full story

Yahoo Finance • 2 years ago

DEADLINE ALERT for HLLY, SCYX, LICY, and FMC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Nov. 30, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story

Yahoo Finance • 2 years ago

SCYNEXIS ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against SCYNEXIS, Inc. and Encourages Investors to Contact the Firm

NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against SCYNEXIS, Inc. (“SCYNEXIS” or the “Company... Full story

Yahoo Finance • 2 years ago

DEADLINE ALERT for OTLK, HLLY, SCYX, LICY: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

BENSALEM, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story

Yahoo Finance • 2 years ago

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against SCYNEXIS, Inc. (SCYX) Investors

LOS ANGELES, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 8, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased... Full story

Yahoo Finance • 2 years ago

ROSEN, SKILLED INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SCYX

NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SCYNEXIS, Inc. (NASDAQ: SCYX) between March 31, 2023 and September 22, 2023, both dates inclusive (t... Full story

Yahoo Finance • 2 years ago

11 Cheapest Stocks With Biggest Upside

In this piece, we will take a look at the 11 cheapest stocks with the biggest upside. If you want to skip our introduction to stock valuation and recent market news, then take a look at 5 Cheapest Stocks With Biggest Upside. Identifying t... Full story

Yahoo Finance • 2 years ago

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SCYX

NEW YORK, Nov. 24, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SCYNEXIS, Inc. (NASDAQ: SCYX) between March 31, 2023 and September 22, 2023, both dates inclusive (t... Full story

Yahoo Finance • 2 years ago

SCYX STOCK NEWS: Investors with Significant Losses in Scynexis, Inc. Should Contact Robbins LLP for Information About the Scynexis, Inc. Class Action

SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Scynexis, Inc. (NASDAQ: SCYX) securities be... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) (NASDAQ: SCYX). Such investors are advised to contact Robert S. Willoughby at newact... Full story

Yahoo Finance • 2 years ago

ROSEN, NATIONAL TRIAL LAWYERS, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SCYX

NEW YORK, Nov. 18, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of SCYNEXIS, Inc. (NASDAQ: SCYX) between March 31,... Full story

Yahoo Finance • 2 years ago

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SCYX

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of SCYNEXIS, Inc. (NASDAQ: SCYX) between March 31,... Full story